
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Generic Threat
Author(s)Kevin Gopal
Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.
Advertisement
Articles in this issue
about 25 years ago
Pharmacies: OTC Price Warsabout 25 years ago
One Disease at a Timeabout 25 years ago
Overview of the Industry: A World of Opportunitiesabout 25 years ago
The Power Shiftabout 25 years ago
A Giant Stumblesabout 25 years ago
Overruled: No More Dual Pricingabout 25 years ago
SubmergedAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
3
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5




